Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index, and 1 are not checked yet.

Trends in glyburide compared with insulin use for gestational diabetes treatment in the united states, 2000-2011

Open access
Camelo Castillo, Wendy, Boggess, Kim, Stürmer, Til, Brookhart, M. Alan, Benjamin, Daniel K., Jonsson Funk, Michele · 2014 · Obstetrics & Gynecology

Abstract

OBJECTIVE: To describe trends and identify factors associated with choice of pharmacotherapy for gestational diabetes (GDM) from 2000-2011 using a healthcare claims database. METHODS: This was a retrospective cohort study of a large nationwide population of commercially insured women with GDM and pharmacy claims for glyburide or insulin before delivery, 2000-2011. We excluded women younger than 15 years or older than 50 years, those with prior noninsulin-dependent diabetes mellitus, or those who had multiple gestations. We estimated trends over time in the use of glyburide compared with insulin and prevalence ratios and 95% confidence intervals (CIs) for the association between covariates of interest and treatment with glyburide compared with insulin. RESULTS: We identified 10,778 women with GDM treated with glyburide (n=5,873) or insulin (n=4,905). From 2000 to 2011, glyburide use increased from 7.4% to 64.5%, becoming the more common treatment in 2007. Women less likely to be treated with glyburide were those with metabolic syndrome (prevalence ratio 0.71, 95% CI 0.50-0.99), hyperandrogenism (prevalence ratio 0.77, 95% CI 0.62-0.97), polycystic ovarian syndrome (prevalence ratio 0.88, 95% CI 0.78-0.99), hypothyroidism (prevalence ratio 0.89, 95% CI 0.83-0.96), or undergoing infertility treatment (prevalence ratio 0.93, 95% CI 0.86-1.02). The probability of receiving glyburide decreased by 5% for every 10-year increase in maternal age (prevalence ratio 0.95, 95% CI 0.91-0.99). Among women prescribed with glyburide, 7.8% switched or augmented to a different drug class compared with 1.1% of insulin initiators. CONCLUSION: Glyburide has replaced insulin as the more common pharmacotherapy for GDM over the past decade among those privately insured. Given its rapid uptake and the potential implications of suboptimal glucose control on maternal and neonatal health, robust evaluation of glyburide's relative effectiveness is warranted to inform treatment decisions for women with gestational diabetes. LEVEL OF EVIDENCE: II.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/aog.0000000000000285

Cites

28 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 119

Metadata

Authors
Camelo Castillo, W., Boggess, K., Stürmer, T., Brookhart, M. A., Benjamin, D. K., & Jonsson Funk, M.
Affiliations
University of North Carolina at Chapel Hill (US)
Venue
Obstetrics & Gynecology
Published
2014-06
Volume
123
Issue
6
Pages
1177-1184
ISSN
0029-7844 (ISSN-L)
OpenAlex
W2096962718
Cited by
118
References
27
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 5 · 2022: 16 · 2021: 23 · 2020: 7 · 2019: 10 · 2018: 14 · 2017: 11 · 2016: 8 · 2015: 17 · 2014: 2
FWCI
13.48
Type
journal article
Language
en
Open access
Locations
  • Obstetrics and Gynecology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Agency for Healthcare Research and Quality (K02HS017950)
  • National Institute on Aging (R01AG042845, R01AG023178)
  • National Cancer Institute (R01CA174453)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R21HD080214, K24HD058735)
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
gestational diabetes mellitus, glibenclamide, insulin, antidiabetic pharmacotherapy, treatment trends, drug switching, metabolic syndrome, polycystic ovary syndrome, hyperandrogenism, hypothyroidism, infertility treatment, maternal age, commercially insured women, prescribing patterns, health insurance claims data, cost-effectiveness
MeSH terms
Adolescent, Adult, Female, Glyburide, Humans, Hypoglycemic Agents, Hypothyroidism, Middle Aged, Practice Patterns, Physicians', Polycystic Ovary Syndrome, Pregnancy, Retrospective Studies, United States, Comorbidity, Multivariate Analysis, Diabetes, Gestational, Hyperandrogenism, Metabolic Syndrome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trends in glyburide compared with insulin use for gestational diabetes treatment in the united states, 2000-2011. https://app.cochat.ai/papers/10.1097/aog.0000000000000285
The paper
Camelo Castillo, W., Boggess, K., Stürmer, T., Brookhart, M. A., Benjamin, D. K., & Jonsson Funk, M. (2014). Trends in glyburide compared with insulin use for gestational diabetes treatment in the united states, 2000-2011. Obstetrics & Gynecology. https://doi.org/10.1097/aog.0000000000000285

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.